Epidermal Growth Factor Receptor Mutation and Lung Cancers, Current Evidence, a Brief Review

With the advances of target therapies, lung cancer patients overall survival had extended from previous 6 months to 2.5 years. Some patients even survived over 5 years more. It is important nowadays for general physicians have some knowledge of this topic. A brief review was conducted. Does EGFR inhibitor more effective in mutant type than chemotherapy? How about subtype? Does EGFR inhibitor more effective in wild type than chemotherapy? Does EGFR inhibitor more effective in mutation type than the wild type? How about subtype? Are there survival benefits of EGFR mutation type versus wild type? EGFR resistant mechanism